- Home
- BYND vs DMAC Comparison
BYND vs DMAC Comparison
Compare BYND & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYND
- DMAC
- Stock Information
- Founded
- BYND 2009
- DMAC 2000
- Country
- BYND United States
- DMAC United States
- Employees
- BYND N/A
- DMAC N/A
- Industry
- BYND Packaged Foods
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- BYND Consumer Staples
- DMAC Health Care
- Exchange
- BYND Nasdaq
- DMAC Nasdaq
- Market Cap
- BYND 293.8M
- DMAC 267.7M
- IPO Year
- BYND 2019
- DMAC N/A
- Fundamental
- Price
- BYND $4.02
- DMAC $6.51
- Analyst Decision
- BYND Sell
- DMAC Strong Buy
- Analyst Count
- BYND 6
- DMAC 3
- Target Price
- BYND $5.50
- DMAC $7.00
- AVG Volume (30 Days)
- BYND 3.3M
- DMAC 81.8K
- Earning Date
- BYND 02-26-2025
- DMAC 03-18-2025
- Dividend Yield
- BYND N/A
- DMAC N/A
- EPS Growth
- BYND N/A
- DMAC N/A
- EPS
- BYND N/A
- DMAC N/A
- Revenue
- BYND $323,473,000.00
- DMAC N/A
- Revenue This Year
- BYND N/A
- DMAC N/A
- Revenue Next Year
- BYND $3.29
- DMAC N/A
- P/E Ratio
- BYND N/A
- DMAC N/A
- Revenue Growth
- BYND N/A
- DMAC N/A
- 52 Week Low
- BYND $3.30
- DMAC $2.14
- 52 Week High
- BYND $12.12
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- BYND 50.32
- DMAC 62.22
- Support Level
- BYND $4.00
- DMAC $5.75
- Resistance Level
- BYND $4.74
- DMAC $6.82
- Average True Range (ATR)
- BYND 0.22
- DMAC 0.30
- MACD
- BYND 0.03
- DMAC 0.02
- Stochastic Oscillator
- BYND 37.39
- DMAC 74.48
About BYND Beyond Meat Inc.
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels, and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.